Tech Company Financing Transactions
Santa Ana Bio Funding Round
Santa Ana Bio closed a $168 million funding round on 6/13/2024. Investors included GV, Versant Ventures and Access Biotechnology.
Transaction Overview
Company Name
Announced On
6/13/2024
Transaction Type
Venture Equity
Amount
$168,000,000
Round
Undisclosed
Investors
GV (Lead Investor)
Versant Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1105 Atlantic Avenue 104
Alameda, CA 94501
USA
Alameda, CA 94501
USA
Phone
Undisclosed
Website
Email Address
Overview
Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Emtage
Chief Financial Officer
Zack McNealy
Chief Technical Officer
Danny Wells
Vice President
Daniel Alvarez
Vice President
Yun Bai
VP - Bus. Development
Timothy Herpin
Browse more venture capital transactions:
Prev: 6/13/2024: Arches venture capital transaction
Next: 6/13/2024: VLogic Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs